



Telomere Length and Cardiovascular Disease: A Precursor Marker and Therapeutic Target

Guest Editors:

Dr. Marios Sagris

Cardiology Clinic, 'Hippokration'
General Hospital, School of
Medicine, National and
Kapodistrian University of
Athens, 15772 Athens, Greece

Prof. Dr. Dimitris Tousoulis

Cardiology Clinic, 'Hippokration'
General Hospital, School of
Medicine, National and
Kapodistrian University of
Athens, 15772 Athens, Greece

Deadline for manuscript
submissions:

22 May 2024

Message from the Guest Editors

Dear Colleagues,

Over the last two decades, the scientific society has been investigating the role of biomarkers in the early detection of atherosclerotic disease. Currently, the investigation of telomeres as a potential tool for the early detection of atherosclerotic disease seems to be a promising method. Telomere length (TL) has been associated with several human disorders and diseases while its attrition rate varies significantly in the population. Therapy targeting telomere length also changed the way that medicine uses the therapeutic arsenal in several conditions, including cardiovascular diseases.

In this Special Issue, we aim to investigate how TL shortening serves as a precursor marker and a potential therapeutic target in cardiovascular disorders, and explore the current and future treatment options based on TL, new advances in pharmacological uses and the relationship between telomere research/biomarker research and drugs. We invite researchers to contribute their expertise and insights in uncovering the multifaceted aspects of TL in cardiovascular health for this comprehensive exploration.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com